Obesity is losing ground on the heart, thanks to pills we swallow without a second thought

Introduction: a study that upends our certainties

A number that doesn't fit our intuition

Dear reader, I write to you with a number that made me re-read the sentence three times. A study published in The Lancet on July 1, 2026 and conducted on nearly one million adults across seven countries reveals that obese people over 40 now have cholesterol and blood pressure levels that come dangerously close to those of people at a normal weight. Not because obesity has stopped being a risk factor. Because we are treating it chemically, quietly, across an entire population.

The team led by Professor Majid Ezzati, of Imperial College London, combed through 110 national health surveys conducted between 1990 and 2024 in England, the United States, Japan, South Korea, Taiwan, Thailand, and Finland. The finding is clear: among 60 to 79-year-olds, the cardiovascular gap between obese and non-obese people has narrowed considerably since the 1990s.

Why this letter, and why now

I chose the open letter format because this topic touches people I know directly, people who have carried excess weight for decades and who live with the diffuse fear of a heart attack. This study does not absolve them. It nuances their fear, without erasing it.

Dr. Lakshya Jain, co-author of the study at Imperial College London, sums up the significance of the work this way: the observed convergence is "largely due to statins and other widely accessible medications", a "major public health success that shouldn't be lost sight of" at a time when new weight-loss medications dominate the headlines.

The mechanism behind the convergence of numbers

Statins everywhere, a mass prescription effort

Researchers observed that in England and the United States, about 70 to 72% of older men with severe obesity (body mass index above 35) were taking cholesterol-lowering medications in the early 2020s, compared with only 40 to 48% of normal-weight men of the same age. This prescription gap explains much of the observed cardiovascular catch-up.

This is no statistical accident. It is the result of decades of systematic screening, prevention campaigns, and a general medical practice that has come to target at-risk patients with near-mechanical rigor. Statins, once reserved for the most severe cases, have become a medical reflex for anyone carrying excess weight past 40.

Better-controlled blood pressure than before

The same pattern shows up for blood pressure. Antihypertensive drugs, prescribed on a large scale since the 2000s, have partly offset the harmful effect of weight on the arteries. The result: blood pressure in obese people over 40 increasingly resembles that of their leaner peers.

But the study also points to a clear limit: in Taiwan and Thailand, this convergence is less pronounced, likely due to unequal access to treatments. The pill works no miracles if it never reaches the patient's mouth.

Young adults, largely absent from the catch-up

Under 40, the gap remains untouched

Here is the part of the study that few outlets pick up: among adults under 40, no significant convergence was observed. The cardiovascular gap between obese people and people of normal weight remains virtually identical to what it was thirty years ago.

The reason is almost trivial: young adults, whether obese or not, rarely receive treatments for hypertension or cholesterol, except in cases of already severe illness. Pharmacological prevention only kicks in, in practice, past a certain age, when the risk becomes statistically too heavy for a health system to ignore.

A demographic time bomb

This means an entire generation is growing up today with untreated excess weight, and it will only gain access to this same medicinal protection ten or twenty years from now. The relief observed among older adults must not mask this deferral of the problem into the future.

The researchers themselves are careful not to present this finding as universally good news. They stress that this study is observational, meaning it establishes a strong correlation but does not formally prove that medications alone explain the entire narrowed gap.

What the study does not say, and what needs clarifying

Obesity remains a risk factor for other diseases

Professor Edward Gregg, also of Imperial College London, was careful to frame the scope of the message: "this does not mean obesity stops increasing the risk of other health problems". Type 2 diabetes, kidney disease, liver damage, and several forms of cancer remain statistically more common among people living with obesity, regardless of their cardiovascular profile.

In other words, the heart may be doing better, but the whole body is not necessarily out of danger. This is an essential nuance that I refuse to obscure, even if it weakens the headline's dramatic punch.

The British Heart Foundation calls for caution

Professor Bryan Williams, of the British Heart Foundation, praised what he called a "public health achievement", while reminding the public of the broader context of obesity-related harm. His message is consistent with that of the Imperial College team: neither minimize the progress, nor treat it as a definitive solution.

This collective caution from the British scientific community stands in contrast to the sensationalism that often accompanies this kind of publication. It is precisely this measured tone that, to my eyes, makes this study credible.

The new context of weight-loss drugs

The massive arrival of GLP-1 agonists

This study lands at a pivotal moment. Drugs in the GLP-1 agonist family, popularized for large-scale weight loss in recent years, are already transforming how Western societies approach obesity. Dr. Jain rightly insists that the success of statins must not be "lost sight of" as these new treatments capture all the media and financial attention.

There is a real risk that public health attention and budgets will drift away from classic cardiovascular treatments — cheap and proven over decades — in favor of newer, costlier molecules whose long-term effects have yet to be fully documented.

Complementary rather than competing

The implicit message of the study is not to choose between statins and new weight-loss treatments, but to understand that they act on different levers. Statins correct the cardiovascular consequences of weight. The new drugs attack the cause itself. Both approaches, combined with discernment, could offer the most complete protection.

But this combination comes at a cost, and that cost is not distributed equally between wealthy and middle-income countries, as shown by the gap already observed between England and the United States on one side, and Taiwan and Thailand on the other.

What this changes for the obese patient over 40

A message of measured hope, not a blank check

For anyone obese over 40 who faithfully takes their statins and blood pressure medication, this study offers a form of validation. The treatment works, at the population level, to reduce the cardiovascular risk gap. That deserves to be said clearly, without rhetorical detours.

But this message does not exempt anyone from rigorous medical follow-up. Professor Ezzati clarified that taking medication "has helped middle-aged and older adults reduce their cardiovascular risk to levels similar to those of people at normal weight", a cautious phrasing that speaks of risk reduction, never elimination.

The irreplaceable role of individual medical follow-up

No population study, however vast, replaces an individual blood panel or a personalized cardiology consultation. The aggregated statistics from 110 surveys across seven countries tell a broad trend, not the medical fate of any one particular person.

This is where I want to insist most strongly in this letter: never let a newspaper headline, however honest, replace your treating physician. The study confirms that the system now works better overall than before. It says nothing about your specific case.

A quiet victory for public health

The invisible work of Western health systems

What this study reveals, in the background, is the effectiveness of a public health system that has, over three decades, generalized screening for cholesterol and blood pressure among at-risk populations. This work never makes headlines, unlike announcements of new miracle drugs.

Systematic screening campaigns in England and the United States, clinical guidelines for early prescription, widespread reimbursement of statins: this entire institutional apparatus, often criticized for its bureaucratic weight, here produces a measurable result across a million people.

A striking contrast with less well-resourced countries

By contrast, the situation in Taiwan and Thailand is a reminder that this success is anything but automatic. It depends directly on a health system's capacity to identify at-risk patients and provide them with continuous treatment, which requires infrastructure, staff, and steady budgets.

The contrast between wealthy and middle-income countries, documented in black and white in this Lancet study, should fuel discussions on global equity in cardiovascular health, a topic too often relegated to the background amid more spectacular crises.

The trap of a single number in public debate

How a good result can be misused

I worry about how this study could be weaponized. Some will see it as justification for easing up on efforts to prevent obesity itself, betting everything on corrective pharmacology. That would be a dangerously partial reading of the data published on July 1, 2026.

The authors themselves anticipated this risk by stressing, in their public statements, that diabetes, kidney and liver disease, and certain cancers remain documented consequences of obesity, regardless of any cardiovascular treatment.

The need for a balanced message in the media

That is why, in this letter, I choose to cite the nuances as much as the spectacular results. A reader who took away only "obesity no longer affects the heart" would have a false, and potentially dangerous, understanding of their own health.

Science communication carries a particular responsibility here: making a complex result accessible without distorting it into a simplistic promise. That is the exercise I am trying to carry out before you, with all the humility that medicine demands.

What this study reveals about our collective priorities

Treating symptoms rather than causes

There is something deeply revealing in the fact that an entire society has managed, in thirty years, to statistically neutralize the cardiovascular effect of obesity through pharmacology, without significantly reducing the prevalence of obesity itself in the general population.

That says a lot about our collective priorities: it is often easier, politically and economically, to fund treatments than to deeply transform the food, urban, and social environment that produces mass obesity.

A societal choice worth naming

I am not criticizing this choice in itself. Treating millions of people symptomatically is real, measurable progress, as this study shows. But we must be honest enough to recognize that this is a risk-management choice, not a resolution of the underlying problem.

Public health decision-makers will, sooner or later, have to weigh continuing to invest massively in the pharmacological treatment of obesity's consequences, or redirecting some of those resources toward primary prevention, slower to bear fruit but potentially more durable.

The methodological limits worth knowing

An observational study, not a clinical trial

It is essential to recall the methodological nature of this work. It is an analysis of 110 national health surveys conducted over several decades, not a randomized clinical trial specifically designed to test the effect of statins on cardiovascular convergence between obese and non-obese people.

This methodological distinction matters. An observational study establishes solid correlations on a large scale, but it can never fully rule out the influence of other confounding factors, such as broad shifts in lifestyle habits or overall improvements in medical care over the period studied.

What the researchers themselves acknowledge

The authors of the study, published under the title "Metabolic traits in obesity and normal BMI in industrialised countries", designed their work with this methodological caution in mind, which explains the measured tone of their public statements after publication.

This methodological rigor, far from weakening the significance of the work, actually strengthens its credibility with the international scientific community, which remains generally skeptical of overly sweeping conclusions on subjects as complex as obesity.

A call not to relax individual vigilance

Everyone's role in the face of these results

Dear reader living with obesity past 40: this study is not telling you to stop watching your weight, your diet, or your physical activity. It is telling you that if you faithfully follow your cholesterol and blood pressure treatment, your cardiovascular risk statistically approaches that of a normal-weight person the same age.

This is a crucial distinction between "cured" and "protected." The first notion does not exist in this study. The second does, and it deserves to be celebrated without being distorted.

The message for those under 40

For younger readers, the message is different and more urgent: don't count on a pharmacological safety net that doesn't yet exist for your age group. Primary prevention, diet, physical activity, and early medical follow-up remain your best tools, in the absence of a system that will prescribe you statins before your forties.

This generational asymmetry, documented in black and white in the Lancet data, should fuel reflection on the age at which preventive medicine actually begins to protect at-risk patients.

What this study changes for future research

Toward more targeted clinical trials

This publication should, by all scientific logic, pave the way for randomized clinical trials specifically designed to test the hypothesis of a statin-induced cardiovascular convergence in obese populations over 40. This type of trial would allow researchers to more rigorously confirm, or refute, the cause-and-effect relationship suggested by the observational data.

It also remains to be understood why this convergence appears more strongly among 60-79 year-olds than among 40-59 year-olds, a question the Imperial College London team has not yet fully resolved in its publication.

Global equity as the next scientific frontier

The contrast between Western results and those of Taiwan and Thailand should also guide future research into barriers to accessing cardiovascular treatments in middle-income countries, a scientific and political undertaking that goes well beyond the scope of this single study.

There is real potential here for applied research: understanding precisely which public policy levers could reproduce, in countries with more limited resources, the partial success observed in England and the United States.

Why this story deserves your attention this week

A rare example of well-documented good news

In a news cycle often dominated by crises, this study offers something rare: solidly documented good news, published in one of the world's most respected medical journals, and corroborated by researchers who refuse easy hype.

This is not a spectacular discovery in the sense of a new miracle drug. It is confirmation, at the scale of nearly a million people, that decades of public health policy produce measurable, lasting results.

The duty to communicate without betrayal

I have tried, in this letter, to convey this nuance to you without drowning it in medical jargon or distorting it into a simplistic promise. This is a difficult exercise, and I do not claim to have perfectly succeeded.

But I prefer this partial honesty to any sensationalist headline that would make you believe obesity has stopped being a major public health problem. It hasn't, and this study, properly read, never claims otherwise.

What frontline clinicians are already observing

The indirect testimony of medical practice

On the ground, general practitioners and cardiologists have for several years confirmed an underlying trend that this study finally quantifies with rigor: obese patients over 40 are increasingly arriving at consultations already on statins and antihypertensive drugs, prescribed upstream by a screening system that has become nearly automatic.

This clinical normalization, invisible in obesity prevalence statistics themselves, is concretely changing the cardiovascular trajectory of millions of patients across England, the United States, Japan, and South Korea, the four countries where access to treatment remains widest according to the study's cross-referenced data.

A constant reminder from cardiologists about the limits of treatment

Cardiologists consulted in the specialized press insist on a point I deliberately repeat several times in this letter: a well-followed pharmacological treatment reduces risk, it never eliminates it. This distinction, repeated by the researchers themselves, should become a reflex for anyone reading up on this subject.

The success quantified by the Lancet study rests entirely on this long-term therapeutic adherence, a human and social factor that varies enormously depending on education level, income, and access to primary care, even within a single wealthy country.

Conclusion: a nuance to remember, not a slogan

What to take away from this study

This Lancet study, published on July 1, 2026 on nearly one million adults across seven countries, shows that statins and antihypertensive drugs have reduced the cardiovascular gap between obese and normal-weight people over 40, particularly among 60-79 year-olds. This is a measurable public health success, carried by decades of systematic prescription.

But this success remains partial, uneven across countries, absent among those under 40, and does nothing to erase the other risks associated with obesity, such as diabetes, kidney and liver disease, and certain cancers.

A measured hope to close on

I end this letter as I began it: with caution. The hope carried by this study is real, but it is measured. It replaces neither individual medical follow-up, nor the need to keep preventing obesity at its source, nor vigilance against the other complications it still causes today.

To you, dear reader, I simply wish that you read this news for what it is: real, documented, but partial progress in a public health battle that is far from over.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits

I am neither a doctor nor an epidemiological researcher. I am a columnist who reads scientific studies published in recognized journals and tries to make them accessible without betraying them. My acknowledged bias is a preference for nuance over sensationalism, which can sometimes make my texts less spectacular than other coverage of the same topic.

I did not have access to the full raw data of the Lancet study, only to press releases, public quotes from researchers, and sourced journalistic coverage. If new scientific clarifications were to further nuance these results, I commit to reporting them in a future piece.

My method for this article

I cross-referenced available information via the detailed press release, specialized health press coverage, and statements directly attributed to researchers at Imperial College London. I did not invent any quote, any figure, or any statement that is not directly attributable to a verifiable public source.

Any scientific nuance I may have oversimplified is my responsibility as a communicator, not that of the researchers cited in this text.

Sources

Primary sources

EurekAlert — Detailed press release on the Lancet study, researcher quotes — July 1, 2026

Imperial College London — News and research on obesity

The Lancet — Scientific journal that published the original study

Secondary sources

The Guardian — Over-40s obesity study on cholesterol and blood pressure — July 2, 2026

STAT News — Detailed analysis of the Lancet study on obesity — July 1, 2026

British Heart Foundation — Reactions and cardiovascular context

News-Medical — General context on obesity and its risks